Samsung Biologics out to set new standard in drugmaking with time-saving CDO platform

[Photo provided by Samsung Biologics Co.]

Samsung Biologics has unveiled an innovative contract development organization (CDO) platform ¡®S-Cellerate¡¯ designed to dramatically shorten the novel drug timeline from cell line development to investigational new drug (IND) submission and process characterization (PC) to biologics license application (BLA).

The platform announced at BioProcess International (BPI), a conference and exhibition for the world's biotech industry, held in Boston on Sept. 20-23, was developed to standardize and quickly support the services required for biopharmaceutical development.

The platform consists of two services. First, the 'S-Cellerate to IND platform service' is for the support of initial cell line development, production process and analysis method development, non-clinical and clinical material production, and IND. Through an optimized process for each development stage, it can take only nine months from cell line development to IND, according to the company.

The second one is 'S-Cellerate to BLA platform service', which is for BLA for commercial sales through PC and process performance qualification (PPQ) in the late development stage.

Samsung Biologics entered the CDO service market in 2018. The company has already won 81 contracts as of the second quarter of 2021, showing its rapid settlement in the market.

Samsung Biologics is attracting attention from customers around the world by providing high-speed and high-quality services with innovative technologies. Since the launch of 'S-CHOice', a new cell line that features significantly improved cell proliferation and viability, in August last year, the company has seen a significant increase in the number of projects based on the new cell line.

[¨Ï Maeil Business Newspaper & mk.co.kr, All rights reserved]